PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients- A Markov Model
Abstract
Authors
I. Borget A. Vergnenegre C. Chouaid